Acuitas Therapeutics Announces Scientific Presentations at the 14th mRNA Health Conference
Vancouver, B.C. – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, today announced it will present new research at the 14th International mRNA Health Conference. The presentations will highlight Acuitas’ latest advancements in LNP delivery technology from improved formulations to specific disease applications such as cancer vaccines and genetic medicines.
The 14th International mRNA Health Conference will be held from November 17-19, 2026 in Boston at the Westin Copley Place. Acuitas’ researchers will share insights into next-generation formulations with more potent and safer profiles and how they are being applied to cancer and multi-valent vaccines and targeted cell delivery.
“Acuitas is focused on enabling the future of mRNA therapies through improving LNP delivery technology and its application in new clinical approaches,” Ying Tam, Chief Scientific Officer. “The research we are presenting at the mRNA Health Conference demonstrates how Acuitas is solving key challenges that will help our partners’ therapeutic programs advance smoothly to the clinic.”
Presentation Details:
- Oral Presentation: Advancing LNP Systems for Clinical Development of mRNA-based Medicines
- Presenter: Ying Tam, Chief Scientific Officer
- Session Title: VII Delivery
- Session Date and Time: November 18, 9:15-9:30 am EST
- Poster Presentation: #67: Development of an Integrated Analytical Workflow for Characterization of Athebody® DARPin Targeted Lipid Nanoparticles
- Presenter: Steve Chang, Research Scientist II
- Session Date and Time: November 17, 17:00 – 18:30 pm EST
- Poster Presentation: #101 Enhanced Biodegradable Lipids Reduce Liver Exposure and Improve Tolerability of mRNA-LNP While Maintaining Potency at Clinically Relevant Dose Levels
- Presenter: Sherry Weppler, Sr. Research Scientist I
- Session Date and Time: November 17, 17:00 – 18:30 pm EST
- Poster Presentation: #111 Lipid Nanoparticles Enabling Potent Immune Response to mRNA Cancer Vaccines
- Presenter: Ghania Chikh, Senior Director, Vaccine Development
- Session Date and Time: November 17, 17:00 – 18:30 pm EST
- Poster Presentation: #48 In vivo effects of mRNA-lipid adducts and mitigation strategies
- Presenter: Razvan Cojocaru, Research Scientist II
- Session Date and Time: November 18, 17:00 – 18:30 pm EST
- Poster Presentation: #104 Evaluation of the Potential for Genotoxicity and Heritable Changes with Acuitas Lipid Nanoparticle Platform Technology
- Presenter: Merete Eisenhardt, Associate Director, Preclinical/Regulatory
- Session Date and Time: November 18, 17:00 – 18:30 pm EST
- Poster Presentation: #114 Advanced LNP Technology for Infectious Disease Vaccines
- Presenter: Ghania Chikh, Senior Director, Vaccine Development
- Session Date and Time: November 18, 17:00 – 18:30 pm EST
More information about the conference can be found on the mRNA Health Conference website.
About Acuitas Therapeutics
Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.
Acuitas’ clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Its technology also enables ONPATTRO® by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy.
Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic therapies such as in vivo CAR T-cells, gene editing therapies across multiple DNA editing technologies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.
For more information, visit www.acuitastx.com.
Media Contact:
Jakub Cikowski